Parker Releases New Indego Therapy Exoskeleton
September 20 2018 - 8:30AM
Parker Hannifin Corporation (NYSE:PH), the global leader in motion
and control technologies, today announced the release of its next
generation Indego Therapy device for use in rehabilitation centers.
The new Indego Therapy is rapidly adjustable and can be
custom-sized and perfectly fitted to patients.
“With the new Indego Therapy offering, we have a much more
compelling value proposition to clinics and rehabilitation centers
both large and small,” said Achilleas Dorotheou, head of the human
motion and control business unit for Parker. “It also includes our
powerful Therapy+ software suite, which received FDA clearance in
February 2018 and provides individualized therapy sessions to
stroke and spinal cord injury patients, all at a significantly
lower price point.”
The Therapy+ software suite, included with each Indego Therapy
device, incorporates control algorithms based on proven motor
learning principles and allows for an individualized,
patient-centric training approach where the device responds to a
patient’s active contribution and assists in gait only when
necessary. Additionally, therapists have a range of customizable
settings within the Therapy+ software suite which allow them to
further tailor the behavior of the system to specific impairment
and gait needs.
Clare Hartigan, a physical therapist at the Shepherd Center, was
one of numerous therapists who provided feedback to Parker
engineers. “One of the best new features of using Indego Therapy is
the ability to rapidly adjust all components while the patient is
in the device, and at any time while sitting or standing. Therapy+
software allows for setting changes during swing and stance phase
for each leg. Whether the goal for the session is gait retraining,
neuromuscular re-ed, strengthening, endurance or mobility with high
dose steps, I can customize settings for exactly what the patient
needs.”
The new Indego Therapy device replaces the existing three device
Indego Therapy Kit offered to hospitals and rehabilitation centers
since 2016, and is now commercially available for customers in the
United States and Europe.
To learn more about Indego Therapy visit
www.indego.com/therapy
About IndegoWith dedicated therapy and personal
use exoskeletons, Indego provides solutions that address the
complete continuum of care – from acute rehabilitation to home and
community ambulation.
Indego Therapy is cleared by the FDA for use with spinal cord
injury patients with injury levels C7 to L5, and for individuals
with hemiplegia (with motor function of 4/5 in at least one upper
extremity) due to cerebrovascular accident (CVA) to perform
ambulatory functions in rehabilitation institutions. Indego
Personal is cleared by the FDA to enable individuals with spinal
cord injury at levels T3 to L5 to perform ambulatory functions in
their home and community. Indego Therapy and Indego Personal are
also commercially available in Europe, having received the CE Mark
in November 2015.
To learn more about Indego Therapy or Indego Personal, visit
www.indego.com
About Parker Hannifin Parker Hannifin is a
Fortune 250 global leader in motion and control technologies. For
more than 100 years the company has engineered the success of its
customers in a wide range of diversified industrial and aerospace
markets. Learn more at www.parker.com or @parkerhannifin.
- Parker Releases New Indego Therapy Exoskeleton
Aidan Gormley, Director, Global Communications and Branding
216/896-3258
aidan.gormley@parker.com
Parker Hannifin (NYSE:PH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Parker Hannifin (NYSE:PH)
Historical Stock Chart
From Apr 2023 to Apr 2024